BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 30118224)

  • 21. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase
    König B; Watson PR; Reßing N; Cragin AD; Schäker-Hübner L; Christianson DW; Hansen FK
    J Med Chem; 2023 Oct; 66(19):13821-13837. PubMed ID: 37782298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Kong SJ; Nam G; Boggu PR; Park GM; Kang JE; Park HJ; Jung YH
    Bioorg Med Chem; 2023 Feb; 79():117154. PubMed ID: 36645952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
    Reßing N; Schliehe-Diecks J; Watson PR; Sönnichsen M; Cragin AD; Schöler A; Yang J; Schäker-Hübner L; Borkhardt A; Christianson DW; Bhatia S; Hansen FK
    J Med Chem; 2022 Nov; 65(22):15457-15472. PubMed ID: 36351184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the Selective Inhibition of Histone Deacetylase 6.
    Rodrigues DA; Thota S; Fraga CA
    Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer Ruthenium Complexes with HDAC Isoform Selectivity.
    Cross JM; Blower TR; Kingdon ADH; Pal R; Picton DM; Walton JW
    Molecules; 2020 May; 25(10):. PubMed ID: 32455529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor.
    Zhang C; Chou CJ
    Org Lett; 2016 Nov; 18(21):5512-5515. PubMed ID: 27759399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatic Ring Fluorination Patterns Modulate Inhibitory Potency of Fluorophenylhydroxamates Complexed with Histone Deacetylase 6.
    Watson PR; Bai P; Wang C; Cragin AD; Hooker JM; Christianson DW
    Biochemistry; 2022 Sep; 61(18):1945-1954. PubMed ID: 36073962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
    Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
    ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
    Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of the first non-hydroxamate selective HDAC6 degraders.
    Keuler T; König B; Bückreiß N; Kraft FB; König P; Schäker-Hübner L; Steinebach C; Bendas G; Gütschow M; Hansen FK
    Chem Commun (Camb); 2022 Oct; 58(79):11087-11090. PubMed ID: 36098075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
    Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes.
    Griffith DM; Szocs B; Keogh T; Suponitsky KY; Farkas E; Buglyó P; Marmion CJ
    J Inorg Biochem; 2011 Jun; 105(6):763-9. PubMed ID: 21496451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
    Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
    ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.